Celcuity Inc CELC has announced a clinical trial collaboration with the MD Anderson Cancer Center, Novartis AG NVS, and Puma Biotechnology Inc PUMA to conduct a Phase 2 clinical trial.
- The open-label Phase 2 trial will evaluate the efficacy and safety of two targeted therapies, Novartis' Tabrecta, a c-Met inhibitor, and Puma's Nerlynx, a pan-HER inhibitor, in patients with previously treated metastatic HER2-negative breast cancer selected with Celcuity's CELsignia Multi-Pathway Activity Test.
- Under the agreement, MD Anderson will serve as the sponsor, and Celcuity will fund the patient-related trial costs.
- Tabrecta and Nerlynx are currently approved by the FDA to treat non-small cell lung cancer and HER2-positive breast cancer, respectively.
- Celcuity expects to obtain interim results 12 to 15 months after the protocol is activated and final results 12 to 15 months later.
- Enrollment will begin in the second quarter of 2021.
- Price Action: CELC shares are up 6.3% at $ 14.62 in premarket on the last check Wednesday.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.